Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 3/20 | 0.49 |
| ▸ | TNKS | O95271 | 2/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.49 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7776875 | 0.84 | TNKS (0.59) | PARP1TNKSTNKS2PARP2WNT3A | |
| SCHEMBL14613050 | 0.81 | BRD4 (0.53) | BRD4PARP1TNKSTNKS2PARP2 | |
| SCHEMBL14612916 | 0.80 | PARP1 (0.43) | BRD4PARP1TNKSTNKS2PARP2 | |
| SCHEMBL4738751 | 0.71 | ALDH1A1 (0.53) | PARP1TNKSTNKS2PARP2WNT3A | |
| SCHEMBL873906 | 0.69 | TNKS (0.71) | PARP1TNKSTNKS2PARP2KDM4E | |
| SCHEMBL960306 | 0.68 | MAPT (0.62) | RNASELBRD4GAAMGAMSI | |
| SCHEMBL27730576 | 0.68 | GAA (0.69) | RNASELPARP1GAAMGAMSI | |
| SCHEMBL30518205 | 0.68 | RNASEL (1.00) | RNASELBRD4GAAPTPN1KDM4E | |
| SCHEMBL14385807 | 0.68 | RNASEL (1.00) | RNASELBRD4GAAPTPN1KDM4E | |
| SCHEMBL12112025 | 0.68 | RNASEL (0.46) | RNASELBRD4PARP1GAAMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153639-B2 | kinase inhibitor; immunotherapy; viricides; function or behavior associated with PI3 kinase such as cancer, immune, cardiovascular, nervous system, metabolism/endocrine and neurological diseases, viral infection, inflammation; 3-(4-Pyridin-4-yl-thieno[3,2-d]pyrimidin-2-yl)-phenol | F. HOFFMAN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-20090209559-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209559-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3CD | RNASEL 2254/4885BRD4 2081/4885PARP1 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.